Arvinas (ARVN) Net Cash Flow Growth (1y) (2018 - 2026)
Powered by 
Analysis
Arvinas (ARVN) Net Cash Flow Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 47.11% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 75.60% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | -100.75% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 149.49% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -104.22% |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - | -79.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -79.35% |
| Mar 31, 2026 | -185.13% |
| Dec 31, 2025 | 170.59% |
| Sep 30, 2025 | 82.16% |
| Jun 30, 2025 | -49.25% |
| Mar 31, 2025 | 91.28% |
| Dec 31, 2024 | -92.27% |
| Sep 30, 2024 | -425.11% |
| Jun 30, 2024 | 268.69% |
| Mar 31, 2024 | -557.46% |
| Dec 31, 2023 | 485.96% |
| Sep 30, 2023 | -42.82% |
| Jun 30, 2023 | -228.16% |
| Mar 31, 2023 | 206.30% |
| Dec 31, 2022 | 65.20% |
| Sep 30, 2022 | -80.48% |
| Jun 30, 2022 | 110.55% |
| Mar 31, 2022 | 81.02% |
| Dec 31, 2021 | -129.51% |
| Sep 30, 2021 | 207.14% |